| Bioactivity | Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1]. |
| In Vivo | Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1]. Animal Model: |
| Name | Mito-apocynin (C11) |
| CAS | 1254044-38-6 |
| Formula | C37H44BrO4P |
| Molar Mass | 663.62 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64. |
Mito-apocynin (C11)
CAS: 1254044-38-6 F: C37H44BrO4P W: 663.62
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.